INMD

NEUTRAL

$13.53 Live

InMode Ltd. · NASDAQ

Target $17.0 (+25.6%)

$12.72 52W Range $16.74

INMD InMode Ltd. - Fundamental Analysis

NEUTRAL

Console Chart News

INMD Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$13.53

Analyst Target

$17.0

+25.6% Upside

52W High

$16.74

52W Low

$12.72

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 12, 2026

Market cap

$857.24M

P/E

9.46

ROE

13.5%

Profit margin

25.3%

Debt/Equity

0.01

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.

Key Strengths

Exceptional gross margins of 78.53%

Virtually debt-free balance sheet (Debt/Equity 0.01)

Extreme short-term liquidity with a Current Ratio of 9.88

Very low valuation relative to sector (P/E 9.46 vs Sector Avg 90.69)

Consistent track record of beating quarterly earnings estimates

Key Risks

Severe earnings contraction (-63.50% YoY)

Strongly bearish technical momentum (0/100 trend score)

Deteriorating fundamental health as indicated by Piotroski F-Score (3/9)

Stagnating revenue growth (6.10% YoY) relative to historical expectations

Significant long-term price erosion (-67.3% over 5 years)

AI Fair Value Estimate

Based on comprehensive analysis

$13.2

-2.4% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Value Trap

Key drivers: Strong balance sheet, Collapsing earnings growth, Bearish technicals, Low P/E

Confidence

90%

Value

85/100

Ref P/E, PEG, Graham Number

Positives

P/E of 9.46 is very low
Price is below Graham Number of $18.63
P/B of 1.25 is conservative

Watchpoints

Price exceeds growth-based intrinsic value of $10.01

Future

20/100

Ref Growth rates

Positives

Slight positive Q/Q revenue growth

Watchpoints

Earnings growth is deeply negative (-63.50% YoY)
Revenue growth is sluggish at 6.10%

Past

30/100

Ref Historical trends

Positives

Consistent earnings beats over 25 quarters

Watchpoints

5-year price change of -67.3%
3-year price change of -61.5%

Health

40/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Near-zero debt
High current and quick ratios

Watchpoints

Piotroski F-Score of 3/9 indicates weak fundamental health

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$13.53

Analyst Target

$17.0

Upside/Downside

+25.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for INMD and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
INMD InMode Ltd. Primary	-67.3%	-61.5%	-4.0%	-11.4%	+3.0%	-1.9%
ABUS Arbutus Biopharma Corporation Peer	+34.8%	+48.0%	+34.4%	+0.9%	+3.2%	+6.6%
FTRE Fortrea Holdings Inc. Peer	-68.8%	-68.8%	+45.4%	-12.7%	+4.8%	-0.7%
AMPH Amphastar Pharmaceuticals, Inc. Peer	-5.1%	-51.1%	-30.7%	-35.2%	-36.4%	-6.0%
AMN AMN Healthcare Services, Inc. Peer	-72.8%	-78.8%	-26.3%	+3.5%	+28.0%	+7.7%

INM

InMode Ltd.

Primary

-67.3%

-61.5%

-4.0%

-11.4%

+3.0%

-1.9%

ABU

Arbutus Biopharma Corporation

Peer

+34.8%

+48.0%

+34.4%

+0.9%

+3.2%

+6.6%

FTR

Fortrea Holdings Inc.

Peer

-68.8%

+45.4%

-12.7%

+4.8%

-0.7%

AMP

Amphastar Pharmaceuticals, Inc.

Peer

-5.1%

-51.1%

-30.7%

-35.2%

-36.4%

-6.0%

AMN

AMN Healthcare Services, Inc.

Peer

-72.8%

-78.8%

-26.3%

+3.5%

+28.0%

+7.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

9.46

8.84

N/A

1.25

2.31

0.84

3.6

$857.24M

Profitability

Profit margins and return metrics

Profit Margin 25.33%

Operating Margin 25.03%

Gross Margin 78.53%

ROE 13.53%

ROA 6.88%

Growth

Revenue and earnings growth rates

Revenue Growth +6.1%

Earnings Growth -63.5%

Q/Q Revenue Growth +6.13%

Q/Q Earnings Growth -67.4%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.01

Low debt

Current Ratio

9.88

Strong

Quick Ratio

8.55

Excellent

Cash/Share

$8.77

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.1B

Gross Margin

78.3%

Op. Margin

25.0%

Net Margin

26.0%

Total Assets

$0.8B

Liabilities

$0.1B

Equity

$0.7B

Debt/Equity

0.12x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

98%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-28

$N/A

2026-02-10

$0.46

+10.4% surprise

2025-11-05

$0.38

+7.0% surprise

2025-07-30

$0.47

+14.5% surprise

Healthcare Sector Comparison

Comparing INMD against 264 companies in the Healthcare sector (20 bullish, 87 neutral, 157 bearish)

P/E Ratio

9.46

This Stock

88.64

Sector Avg

-89.3% (Discount)

Return on Equity (ROE)

13.53%

This Stock

-46.09%

Sector Avg

-129.4% (Below Avg)

Profit Margin

25.33%

This Stock

-19.58%

Sector Avg

-229.3% (Weaker)

Debt to Equity

0.01

This Stock

4.1

Sector Avg

-99.7% (Less Debt)

Revenue Growth

6.1%

This Stock

88.16%

Sector Avg

-93.1% (Slower)

Current Ratio

9.88

This Stock

3.58

Sector Avg

+176.0% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
INMD InMode Ltd.	NEUTRAL	$857.24M	9.46	13.5%	25.3%	$13.53
ABUS Arbutus Biopharma Corporation	BEARISH	$872.03M	-	-38.5%	-237.9%	$4.53	Compare
FTRE Fortrea Holdings Inc.	BEARISH	$877.03M	-	-102.4%	-36.2%	$9.38	Compare
AMPH Amphastar Pharmaceuticals, Inc.	BEARISH	$835.41M	8.96	12.9%	13.6%	$18.18	Compare
AMN AMN Healthcare Services, Inc.	BEARISH	$787.1M	-	-35.9%	-10.1%	$20.49	Compare

INMD InMode Ltd.

NEUTRAL

Mkt Cap

$857M

P/E

9.5

ROE

13.5%

Price

$13.53

Compare with INMD

FTRE Fortrea Holdings Inc.

Compare with INMD

Compare with INMD

AMN AMN Healthcare...

Compare with INMD

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

4 analysts

Canaccord Genuity

2025-12-17

Maintains

Hold Hold

UBS

2025-11-06

Maintains

Neutral Neutral

Past News Coverage

Recent headlines mentioning INMD from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

INMD

INMD InMode Ltd. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!